Barclays Forecasts Strong Price Appreciation for Elevance Health (NYSE:ELV) Stock

Elevance Health (NYSE:ELV) had its price objective raised by research analysts at Barclays from $408.00 to $480.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective indicates a potential upside of 23.82% from the stock’s current price.

A number of other research analysts have also recently weighed in on ELV. Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Robert W. Baird upped their target price on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a research report on Tuesday, February 3rd. Jefferies Financial Group cut their target price on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, The Goldman Sachs Group raised their price target on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $403.11.

Elevance Health Trading Down 1.8%

Elevance Health stock opened at $387.65 on Tuesday. The firm has a market cap of $84.18 billion, a PE ratio of 16.49, a P/E/G ratio of 2.23 and a beta of 0.66. Elevance Health has a 12 month low of $273.71 and a 12 month high of $408.00. The stock’s 50 day simple moving average is $335.93 and its two-hundred day simple moving average is $336.96. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the firm earned $11.97 EPS. The business’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts anticipate that Elevance Health will post 26.91 earnings per share for the current year.

Institutional Trading of Elevance Health

Several large investors have recently bought and sold shares of ELV. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in Elevance Health during the fourth quarter worth about $5,941,000. Evergreen Wealth Management LLC raised its stake in Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after purchasing an additional 4,336 shares during the period. Blume Capital Management Inc. boosted its holdings in Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after purchasing an additional 4,320 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock valued at $149,182,000 after buying an additional 109,462 shares during the period. Finally, Caprock Group LLC purchased a new stake in shares of Elevance Health in the 3rd quarter valued at approximately $1,638,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.